Piper Sandler analyst Edward A. Tenthoff downgraded Fulcrum Therapeutics (NASDAQ: FULC) from Overweight to Underweight with a price target of ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Analyst Comments Downgrades